Parkinson’s disease duration can affect visual field sensitivity
Click Here to Manage Email Alerts
Key takeaways:
- Greater Parkinson’s disease duration was associated with lower sensitivity and greater sensitivity variability on visual field exams.
- The relationship between disease severity and visual field is unclear.
A patient’s duration of Parkinson’s disease can affect visual field sensitivity, according to a poster presented at the North American Neuro-Ophthalmology Society meeting.
“Ocular manifestations of PD have been attributed to retinal dopamine deficiency,” Annika J. Patel and colleagues wrote. “Previous studies suggest PD patients may have worse visual field exam results than non-PD controls.”
Patel and colleagues aimed to correlate visual field findings in patients with Parkinson’s disease (PD) to disease duration and severity. The epidemiological study included 35 eyes of 18 patients diagnosed with PD for any duration or severity with no history of ocular disease affecting visual fields, no family history of glaucoma and best corrected visual acuity of at least 20/200.
Data about patients’ PD duration and severity were collected using electronic health records.
In the study, 68.6% of eyes had reliable visual fields. Greater duration from PD diagnosis and first motor symptoms were correlated with lower mean sensitivity in the overall visual field, as well as in the inferotemporal and inferonasal quadrants and peripheral region.
Patients with reliable visual field exams had higher PD severity off medication than those with unreliable exams.
“Greater PD duration is associated with lower mean sensitivity and greater sensitivity variability on visual field exams, though the relationship with PD severity is unclear,” Patel and colleagues wrote. “Prospective longitudinal studies would be valuable to demonstrate the use of visual field indices as PD biomarkers, though attention should be paid to exam reliability.”
Collapse
Patel AJ, et al. Association between head-mounted visual field results and Parkinson’s disease duration and severity. Presented at: North American Neuro-Ophthalmology Society meeting; March 11-16, 2023; Orlando, Florida.
Read more about
Click Here to Manage Email Alerts